GPT and hypothyroidism: In this study, the most common drug-related adverse events (≥ 5%) of envafolimab in monotherapy were increased AST (16.2%), increased ALT (14.6%), increased blood bilirubin (12.2%), rash (11.7%), and hypothyroidism (10.4%).